16-23626297-GA-GAA
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_024675.4(PALB2):c.2686dupT(p.Ser896PhefsTer32) variant causes a frameshift change involving the alteration of a non-conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. Variant has been reported in ClinVar as Likely pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_024675.4 frameshift
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 31
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Familial cancer of breast Pathogenic:2
Curators: Marc Tischkowitz, Arleen D. Auerbach. Submitter to LOVD: Marc Tischkowitz. -
This variant is considered pathogenic. This variant creates a frameshift predicted to result in premature protein truncation. -
not provided Pathogenic:1
This duplication of one nucleotide in PALB2 is denoted c.2686dupT at the cDNA level and p.Ser896PhefsX32 (S896FfsX32) at the protein level. The normal sequence, with the base that is duplicated in braces, is AGTT[T]CTCT. The duplication causes a frameshift which changes a Serine to a Phenylalanine at codon 896, and creates a premature stop codon at position 32 of the new reading frame. This variant is predicted to cause loss of normal protein function through either protein truncation or nonsense-mediated mRNA decay. PALB2 c.2686dupT has been observed in 3 of 972 individuals with personal and family histories of invasive breast cancer and was not identified in 960 unrelated controls (Casadei 2011). Based on the currently available information, we consider this duplication to be a likely pathogenic variant. -
Hereditary cancer-predisposing syndrome Pathogenic:1
The c.2686dupT pathogenic mutation, located in coding exon 7 of the PALB2 gene, results from a duplication of T at nucleotide position 2686, causing a translational frameshift with a predicted alternate stop codon (p.S896Ffs*32). This mutation has been reported in multiple patients and families with hereditary breast cancer (Casadei S et al. Cancer Res., 2011 Mar;71:2222-9; Antoniou AC et al. N. Engl. J. Med., 2014 Aug;371:497-506). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at